| Literature DB >> 33312438 |
Christos Kourek1, Eleftherios Karatzanos1, Katherina Psarra2, Georgios Georgiopoulos3, Dimitrios Delis1, Vasiliki Linardatou1, Gerasimos Gavrielatos4, Costas Papadopoulos5, Serafim Nanas1, Stavros Dimopoulos6.
Abstract
BACKGROUND: Vascular endothelial dysfunction is an underlying pathophysiological feature of chronic heart failure (CHF). Patients with CHF are characterized by impaired vasodilation and inflammation of the vascular endothelium. They also have low levels of endothelial progenitor cells (EPCs). EPCs are bone marrow derived cells involved in endothelium regeneration, homeostasis, and neovascularization. Exercise has been shown to improve vasodilation and stimulate the mobilization of EPCs in healthy people and patients with cardiovascular comorbidities. However, the effects of exercise on EPCs in different stages of CHF remain under investigation. AIM: To evaluate the effect of a symptom-limited maximal cardiopulmonary exercise testing (CPET) on EPCs in CHF patients of different severity.Entities:
Keywords: Cardiopulmonary exercise testing; Chronic heart failure; Circulating endothelial cells; Endothelial progenitor cells; Maximal exercise; Severity
Year: 2020 PMID: 33312438 PMCID: PMC7701904 DOI: 10.4330/wjc.v12.i11.526
Source DB: PubMed Journal: World J Cardiol
Demographic characteristics and maximal cardiopulmonary exercise testing indices of patients with chronic heart failure of different severity based on peak oxygen uptake
| Patients, | 25 | 24 |
| Gender, males/females | 21/4 | 20/4 |
| Age in yr | 57 ± 10 | 55 ± 9 |
| Height in cm | 174 ± 11 | 175 ± 9 |
| Weight in kg | 92 ± 25 | 87 ± 21 |
| NYHA stage, class II/III | 16/9 | 18/6 |
| EF, % | 32 ± 9 | 32 ± 8 |
| Dilated cardiomyopathy, | 7 (28) | 5 (21) |
| Ischemic, | 14 (56) | 15 (63) |
| Other, | 4 (16) | 4 (17) |
| Diuretics, | 19 (76) | 13 (54) |
| ACE inhibitors, | 11 (44) | 13 (54) |
| ARBs, | 5 (20) | 2 (8) |
| β-Blockers, | 25 (100) | 23 (96) |
| Aldosterone antagonists, | 19 (76) | 18 (75) |
| Peak VO2 in mL/kg/min | 14.5 ± 2.5 | 21.8 ± 2.4a |
| Predicted peak VO2, % | 52 ± 13 | 74 ± 11a |
| VE/VCO2 slope | 34 ± 5 | 33 ± 4 |
| Peak WR in watts | 75 ± 34 | 118 ± 34a |
Group 1: Peak VO2 < 18.0 mL/kg/min, Group 2: Peak VO2 ≥ 18.0 mL/kg/min.
Values are expressed as mean ± SD; Difference between the 2 severity groups for demographic characteristics and cardiopulmonary exercise testing parameters (aP < 0.05). ACE: Angiotensin-converting-enzyme; ARB: Angiotensin II receptor blockers; CPET: Cardiopulmonary exercise testing; CHF: Chronic heart failure; EF: Ejection fraction; NYHA: New York Heart Association; VCO2: Carbon dioxide output; VO2: Oxygen uptake; WR: Work rate.
Figure 1Boolean analysis. A and B: Flow cytometry analysis for the identification of cellular populations using monoclonal antibodies CD45; C: VEGFR2; D: CD34; E: CD133. In all samples, the CD34 expression was weak. CPET: Cardiopulmonary exercise testing; VEGFR2: Vascular endothelial growth factor receptor 2.
Acute mobilization of endothelial cellular populations after a symptom-limited cardiopulmonary exercise testing of two different severity groups according to the median value of peak oxygen uptake
| CD34+/CD45-/CD133+ | 60 (25-76) | 90 (70-103) | 42 (19-73) | 90 (39-118) | 0.329 |
| CD34+/CD45-/CD133+/VEGFR2 | 1 (1-4) | 5 (3-8) | 2 (1-3) | 6 (3-9) | 0.075 |
| CD34+/CD133+/VEGFR2 | 13 (9-17) | 13 (9-26) | 10 (7-18) | 14 (10-19) | 0.257 |
| CD34+/CD45-/CD133- | 186 (141-361) | 488 (247-658) | 218 (158-247) | 311 (254-569) | 0.101 |
| CD34+/CD45-/CD133-/VEGFR2 | 2 (1-2) | 3 (2-5) | 1 (1-2) | 4 (2-6) | 0.471 |
Difference within each severity group.
P < 0.01.
P < 0.001. CPET: Cardiopulmonary exercise testing; VO2: Oxygen uptake.
Figure 2Boxplots representing the acute mobilization of each endothelial cellular population before and after a symptom limited maximal cardiopulmonary exercise testing between two severity groups according to the median value of peak oxygen uptake. Group 1: Peak oxygen uptake (VO2) < 18.0 mL/kg/min; Group 2: Peak VO2 ≥ 18.0 mL/kg/min). aP < 0.05 indicates statistically significantly increase.
Acute mobilization of endothelial cellular populations after a symptom-limited cardiopulmonary exercise testing of different severity groups according to the median value of ventilation/carbon dioxide output slope
| CD34+/CD45-/CD133+ | 62 (41-81) | 95 (81-118) | 31 (18-66) | 70 (33-99) | 0.711 |
| CD34+/CD45-/CD133+/VEGFR2 | 1 (1-3) | 5 (3-8) | 2 (1-4) | 5 (3-8) | 0.311 |
| CD34+/CD133+/VEGFR2 | 10 (7-16) | 13 (10-18) | 12 (8-18) | 16 (9-29) | 0.134 |
| CD34+/CD45-/CD133- | 222 (147-287) | 419 (267-576) | 198 (152-376) | 382 (249-794) | 0.540 |
| CD34+/CD45-/CD133-/VEGFR2 | 1 (1-2) | 3 (2-5) | 1 (1-2) | 4 (3-6) | 0.464 |
Differences within each severity group.
P < 0.01.
P < 0.001. CPET: Cardiopulmonary exercise testing.
Acute mobilization of endothelial cellular populations after a symptom-limited cardiopulmonary exercise testing of two different severity groups according to reduced or mid-ranged ejection fraction
| CD34+/CD45-/CD133+ | 42 (22-75) | 90 (37-106) | 63 (40-76) | 90 (65-103) | 0.888 |
| CD34+/CD45-/CD133+/VEGFR2 | 2 (1-3) | 5 (3-8) | 2 (1-4) | 8(4-8) | 0.507 |
| CD34+/CD133+/VEGFR2 | 11 (7-17) | 14 (10-23) | 15 (9-20) | 13 (9-22) | 0.473 |
| CD34+/CD45-/CD133- | 200 (152-279) | 427 (260-626) | 227 (135-372) | 336 (214-624) | 0.702 |
| CD34+/CD45-/CD133-/VEGFR2 | 1 (1-2) | 3 (2-6) | 1 (1-2) | 3 (2-5) | 0.828 |
Differences within each severity group.
P < 0.01.
P < 0.001. CPET: Cardiopulmonary exercise testing; EF: Ejection fraction.